Insulin Manufacturers, PBMs To Face US House Subcommittee Grilling On Drug Pricing
Executive Summary
Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.
You may also be interested in...
Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform
Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.
Senate Panel Questions Early PBM Response To Repatha Price Cut
Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.
Express Scripts Insulin Program Lowers Cost Sharing With Supplemental Manufacturer Discounts
New wrinkle on lowering out-of-pocket spending differs from point-of-sale rebates and manufacturer copay assistance cards, the PBM says, and is not expected to increase plan costs.